SCHEMBL4204288

SCHEMBL4204288

COc1ccc(NS(=O)(=O)c2ccc(Br)cc2C)c2c1C[C@@H](N(C)C)CC2

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.63
QRFPR Q96P65 1/20 0.63
BRD4 O60885 5/20 0.51
BRD1 O95696 1/20 0.51
BRPF1 P55201 1/20 0.51
BRPF3 Q9ULD4 1/20 0.51
GHSR Q92847 1/20 0.45
WDR5 P61964 2/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
ACLY P53396 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
PKM P14618 1/20 0.39
MYC P01106 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4204887 0.91 HTR6 (0.63) HTR6QRFPRBRD4WDR5ACLY
SCHEMBL4205601 0.90 HTR6 (0.62) HTR6QRFPRBRD4BRD1BRPF1
SCHEMBL4207296 0.89 HTR6 (0.61) HTR6QRFPRBRD4BRD1BRPF1
SCHEMBL4205811 0.86 HTR6 (0.62) HTR6QRFPRBRD1BRPF1CHRM2
SCHEMBL4216893 0.85 HTR6 (0.59) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4205248 0.85 HTR6 (0.66) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4199169 0.85 HTR6 (0.66) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4201090 0.84 HTR6 (0.56) HTR6QRFPRBRD4WDR5CHRM2
SCHEMBL4209406 0.84 HTR6 (0.62) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4199204 0.83 HTR6 (0.56) HTR6QRFPRGHSRWDR5CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D HTR6 1/4885QRFPR 81/4885BRD4 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.